Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Ltd. has announced the quotation of 2,053,311 new ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction and could enhance the company’s market presence and liquidity, potentially impacting its stakeholders positively.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products for oncology, leveraging molecularly targeted radiation (MTR) technology.
YTD Price Performance: 27.45%
Average Trading Volume: 4,346
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.91B
See more insights into TLX stock on TipRanks’ Stock Analysis page.
